Business Description
Compare
Compare
Traded in other countries / regions
383930.Korea IPO Date
2022-11-11Description
DT&CRO Co Ltd conducts a series of consigned research, from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics and medical devices, to analysis, bioactivity, clinical trials, and licensing consulting. provided as a service.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.82 | |||||
Equity-to-Asset | 0.37 | |||||
Debt-to-Equity | 0.65 | |||||
Debt-to-EBITDA | -0.96 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 0.44 | |||||
Beneish M-Score | -5.02 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -12.5 | |||||
3-Year EPS without NRI Growth Rate | -61.1 | |||||
3-Year FCF Growth Rate | -59 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 67.64 | |||||
9-Day RSI | 61.47 | |||||
14-Day RSI | 58.2 | |||||
6-1 Month Momentum % | -20.6 | |||||
12-1 Month Momentum % | 104.18 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.82 | |||||
Quick Ratio | 0.79 | |||||
Cash Ratio | 0.44 | |||||
Days Inventory | 10.65 | |||||
Days Sales Outstanding | 43.22 | |||||
Days Payable | 26.63 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -25.6 | |||||
Shareholder Yield % | -7.36 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | -49.83 | |||||
Operating Margin % | -78.08 | |||||
Net Margin % | -98.41 | |||||
FCF Margin % | -95.07 | |||||
ROE % | -57.37 | |||||
ROA % | -33.58 | |||||
ROIC % | -31.19 | |||||
ROC (Joel Greenblatt) % | -67.33 | |||||
ROCE % | -47.02 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 4.98 | |||||
PB Ratio | 4.15 | |||||
Price-to-Tangible-Book | 4.24 | |||||
EV-to-EBIT | -5.47 | |||||
EV-to-EBITDA | -6.83 | |||||
EV-to-Revenue | 5.52 | |||||
EV-to-FCF | -5.84 | |||||
Earnings Yield (Greenblatt) % | -18.28 | |||||
FCF Yield % | -17.68 |